Surgical insights into Parkinson's disease

Journal of the Royal Society of Medicine

Volumn 99, Issue 5, 2006, Pages 238-244

  Pereira, Erlick A C ^a   Aziz, Tipu Z ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; DIAMORPHINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA;

BASAL GANGLION; BRADYKINESIA; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DYSKINESIA; DYSTONIA; FREEZING; FUNCTIONAL ANATOMY; GENE THERAPY; HISTORY OF MEDICINE; HUMAN; MOTOR DYSFUNCTION; MULTICENTER STUDY; NANOTECHNOLOGY; NEUROSURGERY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SURGICAL RISK; TREATMENT INDICATION;

EID: 33744899850     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.99.5.238     Document Type: Review

References (69)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93
2. Parkinson J. An essay on the shaking palsy. London: Sherwood Neely & Jones, 1817
3. Cotzias GC, Van WM, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9
4. Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004;80:452-8
5. Jackson JH. Observations on the physiology and pathology of hemichorea. Edinburgh Med J 1868;14:294-303
6. Hunt R. Progressive atrophy of the globus pallidus. A contribution to the functions of the corpus striatum. Brain 1917;40:58-148
7. Wilson SAK. An experimental research into the anatomy and physiology of the corpus striatum. Brain 1914;36:427-92
8. Horsley V, Clarke RH. The structure and functions of the cerebellum examined by a new method. Brain 1908;31:45-124
9. Wilson SAK. Disorders of motility and muscle tone with special reference to the striatum. Lancet 1925;ii:1-10
10. Bucy PC, Case TJ. Tremor: Physiologic mechanism and abolition by surgical means. Arch Neurol Psychiat 1939;41:721-46
11. Clower WT. Lesions as therapy: surgical intervention in Parkinson's disease prior to L-dopa. J Hist Neurosci 2002;11:375-91
12. Meyerson A, Berlin DD. Case of postencephalitic Parkinson's disease treated by total thyroidectomy. N Engl J Med 1934;210:1205-6
13. Laitinen LV. Surgical treatment, past and present, in Parkinson's disease. Acta Neurol Scand Suppl 1972;51:43-58
14. Cooper IS. Ligation of the anterior choroidal artery for involuntary movements: parkinsonism. Psychiatr Q 1953;27:317-19
15. Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on human brain. Science 1947;106:349-50
16. Leksell L. A stereotaxic apparatus for intracerebral surgery. Acta Chir Scand 1949;99:229-33
17. Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotatic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Scand 1960;35:358-77
18. Laitinen LV. Leksell's unpublished pallidotomies of 1958-1962. Stereotact Funct Neurosurg 2000;74:1-10
19. Hassler R, Riechert T. Indikationen und Lokalisations methode der gezielten Hirnoperationene. Nervenarzt 1954;25:441
20. de Bie RM, de Haan RJ, Schuurman PR, Esselink RA, Bosch DA, Speelman JD. Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review. Neurology 2002;58:1008-12
21. Matsumoto K, Shichijo F, Fukami T. Long-term follow-up review of cases of Parkinson's disease after unilateral or bilateral thalamotomy. J Neurosurg 1984;60:1033-44
22. Marsden CD. Primate models of neurological disorders. Introduction. Adv Neurol 1975;10:3-4
23. Sherrington CS. Decerebrate rigidity and reflex co-ordination of movements. J Physiol 1898;22:319-32
24. Aring CD, Fulton JF. Relation of the cerebrum to the cerebellum: Cerebellar tremor in the monkey and its absence after removal of the principal excitable areas of the cerebral cortex (Areas 4 and 5a, upper part); Accentuation of cerebellar tremor following lesions of the premotor area (Area 6a, upper part). Arch Neurol Psychiat 1936; 35:439-66
25. Denny-Brown D. The Basal Ganglia and Their Relation To Disorders of Movement. Oxford: Oxford University Press, 1962
26. Carlsson A, Lindquist M, Magnusson T. 3,4-Dihydroxy-phenylalanine and 5-hydroxytryptophan as reverse antagonists. Nature 1957;180:1200-1
27. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80
28. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci U S A 1983;80:4546-50
29. Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 1989;112:1533-48
30. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-5
31. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75
32. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-71
33. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Arbizu J, Gimenez-Amaya JM. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 2002;17:51-5
34. Ring HA, Serra-Mestres J. Neuropsychiatry of the basal ganglia. J Neurol Neurosurg Psychiatry 2002;72:12-21
35. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-8
36. Aziz TZ, Peegs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991;6:288-92
37. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61
38. Bingaman KD, Bakay RA. The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies. Prog Brain Res 2000;127:267-97
39. Collier TJ, Steece-Collier K, Kordower JH. Primate models of Parkinson's disease. Exp Neurol 2003;183:258-62
40. Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosc Meth 2004;139:121-43
41. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004;19:743-54
42. Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000;47(Suppl 1):S79-89
43. Jenner P. The MPTP-treated primate as a model of motor complications in Parkinson's disease: primate model of motor complications. Neurology 2003;61(Suppl 3):S4-11
44. Cooper IS. Effect of chronic stimulation of anterior cerebellum on neurological disease. Lancet 1973;i:206
45. Benabid AL, Pollak P, Louveau A, Henry S, de Rougement J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987;50:344-6
46. Walter BL, Vitek JL. Surgical treatment for Parkinson's disease. Lancet Neurol 2004;3:719-28
47. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9
48. Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002;17(Suppl 3):S94-101
49. Stowe RL, Wheatley K, Clarke CE, et al. Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry 2003;74:519-21
50. [http://www. pdsurg.bham.ac.uk]
51. Okun MS, Foote KD. Subthalamic Nucleus vs Globus Pallidus Interna Deep Brain Stimulation, the Rematch. Arch Neurol 2005;62:533-6
52. Jahanshahi M, Ardouin CMA, Brown RG, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2005;123:1142-54
53. Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiat 2005;76:1188-93
54. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-88
55. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiat 2005;76:1217-21
56. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 1994;117:877-97
57. Brown P, Marsden CD. What do the basal ganglia do? Lancet 1998;351:1801-4
58. Brown P. Oscillatory nature of human basal ganglia activity: Relationship to the pathophysiology of Parkinson's disease. Movement Disorders 2003;18:357-63
59. Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 2004;15:2621-4.
60. Jenkinson N, Nandi D, Aziz TZ, Stein JF. Pedunculopontine nucleus: a new target for deep brain stimulation for akinesia. Neuroreport 2005;16:1875-6
61. Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 2005;16:1883-7
62. Bjorklund A, Dunnett SB, Brundin P, et al. Neurol transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003;2:437-45
63. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14
64. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710-19
65. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-8
66. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002;22:10302-12
67. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg Neurol 2004;61:216-20
68. Leary SP, Liu CY, Yu C, Apuzzo ML. Toward the emergence of nanoneurosurgery: part 1-progress in nanoscience, nanotechnology, and the comprehension of events in the mesoscale realm. Neurosurgery 2005;57:606-34
69. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16